Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O.

Int J Cancer. 2019 Nov 20. doi: 10.1002/ijc.32803. [Epub ahead of print]

PMID:
31749145
2.

The Influence of Sexual Arousal on Self-Reported Sexual Willingness and Automatic Approach to Models of Low, Medium, and High Prior Attractiveness.

Borg C, Pawłowska A, van Stokkum R, Georgiadis JR, de Jong PJ.

J Sex Res. 2019 Nov 15:1-13. doi: 10.1080/00224499.2019.1687641. [Epub ahead of print]

PMID:
31729895
3.

Evolutionarily Conserved Interactions within the Pore Domain of Acid-Sensing Ion Channels.

Kasimova MA, Lynagh T, Sheikh ZP, Granata D, Borg CB, Carnevale V, Pless SA.

Biophys J. 2019 Sep 6. pii: S0006-3495(19)30755-6. doi: 10.1016/j.bpj.2019.09.001. [Epub ahead of print]

PMID:
31630811
4.

Assessment of implicit language and theory of mind in multiple sclerosis.

Chanial C, Basaglia-Pappas S, Jacqueline S, Boulange A, Gourdon C, Donya S, Fagnou S, Laurent B, Camdessanche JP, Borg C.

Ann Phys Rehabil Med. 2019 Oct 3. pii: S1877-0657(19)30142-3. doi: 10.1016/j.rehab.2019.08.005. [Epub ahead of print]

PMID:
31586684
5.

[Radiologic response assessment in metastatic colorectal cancers].

Fabre A, Badet N, Calame P, Delabrousse E, Wespiser M, Turco C, Borg C, Jary M.

Bull Cancer. 2019 Nov;106(11):1029-1038. doi: 10.1016/j.bulcan.2019.08.013. Epub 2019 Sep 27. Review. French.

PMID:
31570214
6.

Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Loyon R, Jary M, Salomé B, Gomez-Cadena A, Galaine J, Kroemer M, Romero P, Trabanelli S, Adotévi O, Borg C, Jandus C.

Front Immunol. 2019 Sep 6;10:2121. doi: 10.3389/fimmu.2019.02121. eCollection 2019.

7.

The Reciprocal Relationship Between Sexual Arousal and Disgust as Evidenced in Automatic Approach-Avoidance Behavior.

Hinzmann J, Borg C, Verwoerd JRL, de Jong PJ.

J Sex Res. 2019 Sep 3:1-13. doi: 10.1080/00224499.2019.1658064. [Epub ahead of print]

PMID:
31478756
8.

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y.

Int J Cancer. 2019 Dec 1;145(11):3112-3125. doi: 10.1002/ijc.32620. Epub 2019 Aug 31.

PMID:
31396953
9.

Comparison of Molecular and Histologic Ultrastaging Methods in Sentinel Lymph Node Analysis from Clinical Stage II Colon Cancers.

Deroo O, Lakkis Z, Paquette B, Grand D, Monnien F, Felix S, Borg C, Heyd B, Kim S, Valmary-Degano S.

Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):e65-e70. doi: 10.1097/PAI.0000000000000624.

PMID:
31393285
10.

Toward an optimal quantitative design method integrating user-centered qualitative attributes.

Bertheaux C, Toscano R, Fortunier R, Borg C.

Food Sci Nutr. 2019 May 29;7(7):2261-2270. doi: 10.1002/fsn3.1058. eCollection 2019 Jul.

11.

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T.

Clin Colorectal Cancer. 2019 Sep;18(3):200-208.e1. doi: 10.1016/j.clcc.2019.04.006. Epub 2019 May 3.

PMID:
31311761
12.

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2357-2363. doi: 10.1007/s00432-019-02970-8. Epub 2019 Jul 4.

PMID:
31273511
13.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J.

Gastric Cancer. 2019 Jul 2. doi: 10.1007/s10120-019-00983-3. [Epub ahead of print]

PMID:
31267360
14.

Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.

De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K.

Future Oncol. 2019 Aug;15(23):2723-2731. doi: 10.2217/fon-2019-0243. Epub 2019 Jun 25.

15.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
16.

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

Lakkis Z, Vernerey D, Mege D, Faucheron JL, Panis Y, Tuech JJ, Lefevre JH, Brouquet A, Dumont F, Borg C, Woronoff AS, Meurisse A, Heyd B, Rullier E; French Research Group of Rectal Cancer Surgery (GRECCAR).

Br J Surg. 2019 Jul;106(8):1087-1098. doi: 10.1002/bjs.11176. Epub 2019 May 10.

PMID:
31074509
17.

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC.

Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.

18.

Correction: The influence of olfactory disgust on (Genital) sexual arousal in men.

Borg C, Oosterwijk TA, Lisy D, Boesveldt S, de Jong PJ.

PLoS One. 2019 Mar 19;14(3):e0214330. doi: 10.1371/journal.pone.0214330. eCollection 2019.

19.

Back trauma resulting in commotio cordis.

Bugeja J, Dimech T, Borg C, Meilak S, Sammut M, Grech V.

Images Paediatr Cardiol. 2018 Apr-Jun;20(2):5-6. No abstract available.

20.

The influence of olfactory disgust on (Genital) sexual arousal in men.

Borg C, Oosterwijk TA, Lisy D, Boesveldt S, de Jong PJ.

PLoS One. 2019 Feb 28;14(2):e0213059. doi: 10.1371/journal.pone.0213059. eCollection 2019. Erratum in: PLoS One. 2019 Mar 19;14(3):e0214330.

21.

EMT is associated with an epigenetic signature of ECM remodeling genes.

Peixoto P, Etcheverry A, Aubry M, Missey A, Lachat C, Perrard J, Hendrick E, Delage-Mourroux R, Mosser J, Borg C, Feugeas JP, Herfs M, Boyer-Guittaut M, Hervouet E.

Cell Death Dis. 2019 Feb 27;10(3):205. doi: 10.1038/s41419-019-1397-4.

22.

Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O.

Oncoimmunology. 2018 Oct 19;8(2):e1527498. doi: 10.1080/2162402X.2018.1527498. eCollection 2019.

23.

Biologie, concepts et principes des CAR-T cells.

Rubio MT, Galaine J, Borg C, Daguindau É.

Bull Cancer. 2018 Dec;105 Suppl 2:S135-S146. doi: 10.1016/S0007-4551(19)30044-X. French.

PMID:
30686352
24.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
25.

ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes.

Claude-Taupin A, Fonderflick L, Gauthier T, Mansi L, Pallandre JR, Borg C, Perez V, Monnien F, Algros MP, Vigneron M, Adami P, Delage-Mourroux R, Peixoto P, Herfs M, Boyer-Guittaut M, Hervouet E.

Cells. 2018 Dec 6;7(12). pii: E248. doi: 10.3390/cells7120248.

26.

Comment on: Ventral hernia surgery in morbidly obese patients, immediate or after bariatric surgery preparation: Results of a case-matched study.

Borg CM.

Surg Obes Relat Dis. 2019 Jan;15(1):88-90. doi: 10.1016/j.soard.2018.10.023. Epub 2018 Nov 2. No abstract available.

PMID:
30527890
27.

Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2019 Mar;12(2):581. doi: 10.1038/s41385-018-0121-5.

PMID:
30518781
28.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2019 Apr 1;25(7):2109-2115. doi: 10.1158/1078-0432.CCR-18-2984. Epub 2018 Nov 30.

PMID:
30504426
29.

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y.

Oncotarget. 2018 Oct 23;9(83):35394-35407. doi: 10.18632/oncotarget.26247. eCollection 2018 Oct 23.

30.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C.

JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465.

31.

Does Sleeve Gastrectomy Cause Barrett's Oesophagus?

Mahawar KK, Carr WRJ, Borg CM, Aminian A.

Obes Surg. 2018 Dec;28(12):4049-4050. doi: 10.1007/s11695-018-3541-0. No abstract available.

PMID:
30280332
32.

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B.

World J Clin Oncol. 2018 Sep 14;9(5):110-118. doi: 10.5306/wjco.v9.i5.110.

33.

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F.

Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.

34.

Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F.

Invest New Drugs. 2019 Apr;37(2):375-377. doi: 10.1007/s10637-018-0659-9. Epub 2018 Aug 25.

PMID:
30145624
35.

Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y.

Hum Gene Ther. 2018 Oct;29(10):1202-1212. doi: 10.1089/hum.2018.091.

PMID:
30136612
36.

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J.

Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19.

37.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.

PMID:
30042063
38.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
39.

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2018 Sep;11(5):1408-1419. doi: 10.1038/s41385-018-0049-9. Epub 2018 Jun 15. Erratum in: Mucosal Immunol. 2018 Dec 5;:.

40.

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F.

Oncotarget. 2018 May 22;9(39):25617-25629. doi: 10.18632/oncotarget.25424. eCollection 2018 May 22.

41.

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Lauret Marie-Joseph E, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L.

Oncoimmunology. 2018 Mar 15;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981. eCollection 2018.

42.

Effect of Emotion and Type of Encoding on Memory for Actions: Verbal and Subject-Performed Tasks.

Borg C, Bouazza Z, Godeau M, Getenet JC, Chainay H.

Dement Geriatr Cogn Disord. 2018;45(3-4):162-179. doi: 10.1159/000488103. Epub 2018 May 29.

PMID:
29843134
43.

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C.

Oncoimmunology. 2018 Mar 19;7(5):e1424673. doi: 10.1080/2162402X.2018.1424673. eCollection 2018.

44.

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E.

Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018.

45.

Pain and emotion as predictive factors of interoception in fibromyalgia.

Borg C, Chouchou F, Dayot-Gorlero J, Zimmerman P, Maudoux D, Laurent B, Michael GA.

J Pain Res. 2018 Apr 19;11:823-835. doi: 10.2147/JPR.S152012. eCollection 2018.

46.

Relationship between domestic smoking and metals and rare earth elements concentration in indoor PM2.5.

Drago G, Perrino C, Canepari S, Ruggieri S, L'Abbate L, Longo V, Colombo P, Frasca D, Balzan M, Cuttitta G, Scaccianoce G, Piva G, Bucchieri S, Melis M, Viegi G, Cibella F; RESPIRA Collaborative Project Group; Indoor and Outdoor Air Quality and Respiratory Health in Malta and Sicily - RESPIRA Study Group:, Balzan M, Bilocca D, Borg C, Montefort S, Zammit C, Bucchieri S, Cibella F, Colombo P, Cuttitta G, Drago G, Ferrante G, L'Abbate L, Grutta S, Longo V, Melis MR, Ruggieri S, Viegi G, Minardi R, Piva G, Ristagno R, Rizzo G, Scaccianoce G.

Environ Res. 2018 Aug;165:71-80. doi: 10.1016/j.envres.2018.03.026. Epub 2018 Apr 16.

PMID:
29674239
47.

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C.

Oncoimmunology. 2018 Jan 17;7(4):e1412030. doi: 10.1080/2162402X.2017.1412030. eCollection 2018.

48.

Practices Concerning Revisional Bariatric Surgery: a Survey of 460 Surgeons.

Mahawar KK, Nimeri A, Adamo M, Borg CM, Singhal R, Khan O, Small PK.

Obes Surg. 2018 Sep;28(9):2650-2660. doi: 10.1007/s11695-018-3226-8.

PMID:
29616464
49.

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays.

Guidicelli G, Visentin J, Franchini N, Borg C, Merville P, Couzi L, Taupin JL.

HLA. 2018 Jun;91(6):507-513. doi: 10.1111/tan.13263.

PMID:
29604172
50.

Disgust Toward Sex-Relevant and Sex-Irrelevant Stimuli in Pre-, Early, and Middle Adolescence.

Borg C, Hinzmann J, Heitmann J, de Jong PJ.

J Sex Res. 2019 Jan;56(1):102-113. doi: 10.1080/00224499.2018.1445694. Epub 2018 Mar 27.

PMID:
29583025

Supplemental Content

Support Center